Interestingly, while these triple-engineered iPSC-NK cells demonstrate potent anti-tumor activity in vitro, they were no better than iPSC-NK cells with just the engineered CD16 and IL15 receptor (and not the CD38-KO) in killing tumor cells in vivo using myeloma and AML xenograft models (40). The gene discussed is CD38; the disease is plasma cell myeloma.